Polycystic Ovarian Syndrome Drugs Global Industry Overview and Competitive Landscape till 2032

According to the latest market report published by Persistence Market Research titled 'Polycystic Syndrome Drugs Market: Global Industry Analysis and Forecast, 2016-2024', the global polycystic syndrome drugs market is expected to register a CAGR of 4.6% during the forecast period 2016-2024 and is expected to expand 1.5x in terms of revenue by 2024. The report analyzes the global PCOS drugs market performance and provides information on key drivers and trends likely to impact the market during the forecast period.
Growth of the global polycystic syndrome drugs market is mainly driven by increasing prevalence of the disease and a growing awareness among the patient population. Increasing purchasing power among people and rising awareness of PCOS are factors expected to drive growth of the global PCOS drugs market.

Request For Free Sample Report of "Polycystic Ovarian Syndrome Drugs Market"@ https://www.persistencemarketresearch.com/samples/3682

The need for effective management of diseases associated with PCOS such as hirsutism, obesity, and infertility is likely to boost the demand for PCOS drugs. Also, a growing popularity of combination drugs and their rising adoption among the patient population is expected to boost revenue growth of the PCOS drugs market in the coming years.

A rising expenditure on research and development activities and introduction of novel drugs is further expected to boost growth of the global polycystic syndrome drugs market over the forecast period. However, lack of FDA approved drugs, a low level of awareness of PCOS in underdeveloped countries, and increasing side effects associated with generics might hamper market growth during the forecast period.

The global market for PCOS drugs presents several growth opportunities for market players. There is a good growth potential in emerging markets and pharmaceutical drugs manufacturers are focusing on emerging economies in the Asia Pacific and Africa such as Kenya, Nigeria, etc. to target a large patient population. Also, effective reimbursement policies and reduction in the costs of drugs used for the treatment of PCOS is likely to increase the adoption of PCOS drugs across the globe.

Companies
Novartis AG
Sanofi.
Teva Pharmaceutical Industries Limited
Merck & Co., Inc. (Merck group)
AstraZeneca plc
Bayer AG
Abbott
Pfizer, Inc.
Bristol-Myer Squibb Company
Ferring Pharmaceuticals, Inc.
Johnson and Johnson
Mylan N.V.
Allergan plc.
GlaxoSmithKline
Lupin Pharmaceuticals
AbbVie
Takeda
BIOCAD Global
Blairex Laboratories Inc.
Agile Therapeutics

Buy Full Report Now and Get Up to 20% Discount @ https://www.persistencemarketresearch.com/checkout/3682

Leading market players are also investing significantly in developing new branded drugs to treat PCOS, owing to an anticipated high rise in the global patient population. The demand for branded PCOS drugs is likely to increase significantly during the forecast period.

The global PCOS drugs market is segmented based on Drug Class into Oral Contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors, and Diuretics. The contraceptive drug class segment is projected to register a CAGR of 5.4% over the forecast period.

Oral contraceptives are generally the preferred first line therapy for the treatment of PCOS as they are easily available as OTC drugs. The insulin sensitizing agent segment is expected to register a CAGR of 4.8% over the forecast period. About 70% of PCOS patients are overweight and are in the category of possible candidates for type 2 diabetes.

Key Questions Answered in This Report.
• What are the Roadblocks for Polycystic Ovarian Syndrome Drugs Suppliers?
• What are the Key Opportunities for Polycystic Ovarian Syndrome Drugs Manufacturers?
• How is Focus on Safety Influencing Polycystic Ovarian Syndrome Drugs Demand?
• What is the Regulatory Impact on Global Sales of Polycystic Ovarian Syndrome Drugs?
• Which Region Offers the Largest Opportunity for Sales of Polycystic Ovarian Syndrome Drugs?
• Where Does the U.S. Stand in the Market for Polycystic Ovarian Syndrome Drugs?
• What Is the Outlook for Polycystic Ovarian Syndrome Drugs Manufacturers in China?
• Why is Germany a Lucrative Market for Polycystic Ovarian Syndrome Drugs Manufacturers?
• Why Will Belgium Outpace Other European Markets for Polycystic Ovarian Syndrome Drugs?
• Why is There High Demand for Tires in Polycystic Ovarian Syndrome Drugs?
• Why are Sales of Polycystic Ovarian Syndrome Drugs Surging?

Request Customization @ https://www.persistencemarketresearch.com/request-customization/3682

Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com

About Us
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.